

SUPPLEMENTARY MATERIAL TO:

Differential abnormalities of cerebrospinal fluid dopaminergic vs. noradrenergic indices in synucleinopathies

David S. Goldstein, MD PhD, Patti Sullivan, CMT, Courtney Holmes, CMT

Guillaume Lamotte, MD, Abhishek Lenka, MD PhD, Yehonatan Sharabi, MD

Autonomic Medicine Section, Clinical Neurosciences Program, Division of Intramural Research, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD

Email addresses: PS=psullivan1@ninds.nih.gov; CH=courtneysh54@gmail.com; GL=guillaume.lamotte@nih.gov; AL=abhishek.lenka@nih.gov; YS=yehonatan.sharabi@sheba.health.gov.il

Short title: CSF Biomarkers of Catecholamine Deficiency

Keywords: norepinephrine; Parkinson; multiple system atrophy; pure autonomic failure; MHPG; HVA

Corresponding author: David S. Goldstein, MD PhD, *Autonomic Medicine Section*, NINDS, NIH, 10 Center Drive MSC-1620, Building 10 Room 8N260, Bethesda, MD 20892-1620 USA. Phone: 301-496-210. Fax: 301-402-0180. iPhone: 301-675-1110. e-mail: goldsteind@ninds.nih.gov. ORCID ID=0000-0002-5709-9940.

Supplementary Table 1:

Cerebrospinal fluid (CSF) catechols, 3-methoxy-4-hydroxyphenylglycol (MHPG), and homovanillic acid (HVA) data were analyzed from 130 subjects, including 92 synucleinopathy patients (36 Parkinson disease (PD), 37 multiple system atrophy (MSA), 19 pure autonomic failure (PAF)). Mean (\pm SEM) ages and sex makeups were: PD 65 \pm 2 years, 22 men, 14 women; MSA 57 \pm 1 years, 25 men, 12 women; and PAF 65 \pm 2 years, 14 men, 5 women. Detailed clinical information is provided about the three synucleinopathy groups, including treatment status for a variety of potentially interfering medications (e.g., a monoamine oxidase inhibitors (MAOI), catechol-O-methyltransferase inhibitor (COMTI), or selective serotonin reuptake inhibitor (SSRI)).

